Dose-response assessment of PFAS mixtures in relation to biomarkers of effects relevant for cardiovascular disease in humans

(1) To identify associations between available PFAS concentration data in human serum and corresponding serum lipids and metabolomics data, (2) To establish dose-response relationships between serum data on PFAS concentrations and metabolomics observations of relevance for cardiovascular disease, (3) To utilize the metabolomics dose-response data for further development of adverse outcome pathways (AOPs) of relevance for cardiovascular disease, and 4) To include all the generated mechanistic and quantitative information into a probabilistic assessment of cardiovascular disease risk following exposure to individual PFAS or PFAS-mixtures.